In comparative medicine, veterinary researchers have applied the immunophenotypes adopted from human breast cancer (HBC) to CMT using protein biomarkers such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Here, ERBB2 is linked to breast cancer.